By Trend News Line 2024-03-19 11:30:00.
Heart & Lung Health Network Partners with Caristo Diagnostics to Offer Revolutionary CaRi-Heart® AI Technology
You may also like to watch : Who Is Kamala Harris? Biography - Parents - Husband - Sister - Career - Indian - Jamaican Heritage
In an exciting development in the field of cardiac diagnostics, Heart & Lung Health (HLH), a UK-wide network of expert cardiothoracic radiologists, has teamed up with Caristo Diagnostics to introduce the groundbreaking CaRi-Heart® AI technology. This innovative solution is set to revolutionize the prediction of patients’ risk of developing potentially fatal coronary artery disease.
Unveiling CaRi-Heart® AI Technology
With over 110 skilled cardiothoracic radiologists within its network, HLH is at the forefront of providing specialized cardiac health services across the UK. By partnering with Caristo Diagnostics, a leading cardiac disease diagnostics company, HLH aims to offer the cutting-edge CaRi-Heart® AI technology to patients in multiple sites nationwide.
The Need for Advanced Cardiac Risk Assessment
You may also like to watch: Is US-NATO Prepared For A Potential Nuclear War With Russia - China And North Korea?
Every year, an estimated 1 million adults in the UK experience chest pain, prompting many to undergo coronary computed tomography angiography (CCTA) scans to diagnose coronary artery disease. However, a significant number of patients undergoing these scans show no clear signs of significant narrowing, leading to a false sense of security regarding their risk of heart attack.
The Role of CaRi-Heart® Technology
CaRi-Heart® AI technology, developed based on research from the University of Oxford, is a pioneering solution that can detect coronary inflammation – a critical risk factor previously unseen in routine CCTAs. By assessing coronary inflammation and integrating plaque and clinical risk factors such as cholesterol levels, CaRi-Heart® provides a non-invasive Fat Attenuation Index Score™ (FAI-Score™) as a patented biomarker for identifying patients at risk.
Impact of CaRi-Heart® on Patient Outcomes
Recent research studies have demonstrated that patients with abnormal CaRi-Heart® test results, even in the absence of plaque and calcium, face significantly higher risks of cardiac mortality and major adverse cardiac events (MACEs) compared to those with normal results. This highlights the potential of CaRi-Heart® in identifying at-risk individuals early on and potentially saving thousands of lives.
Expansion of CaRi-Heart® Access
By incorporating the CaRi-Heart® AI technology into its cardiac health check package, HLH aims to provide widespread access to this advanced diagnostic tool. Patients screened with CaRi-Heart® by HLH radiologists will benefit from personalized care managed by their consulting cardiologists or family doctors.
Pioneering Partnership for Improved Patient Care
The collaboration between HLH and Caristo Diagnostics marks a significant step towards enhancing cardiac risk assessment and management in the UK. With a focus on early diagnosis and intervention, the partnership aims to improve health outcomes for patients at risk of coronary artery disease.
Exciting Future Prospects
As Caristo Diagnostics continues to lead in cardiac and vascular disease diagnostics, the integration of CaRi-Heart® technology into routine clinical practice holds promise for transforming risk stratification and patient management. With a track record of exceptional validation results and recognition in leading medical journals, CaRi-Heart® is poised to make a lasting impact on the field of cardiac diagnostics.
In conclusion, the partnership between HLH and Caristo Diagnostics heralds a new era in cardiac health assessment in the UK, offering patients access to cutting-edge technology for early detection and management of coronary artery disease. With a focus on precision and patient care, this collaboration sets a new standard for cardiac risk assessment and highlights the potential for improved outcomes in the fight against heart disease..
– Long-tailed: “Heart and Lung Health selects Caristo Diagnostics AI technology for early diagnosis of coronary artery disease”
– Long-tailed: “Caristo Diagnostics AI technology chosen by Heart & Lung Health for UK-wide early diagnosis of coronary artery disease”.
